New Munich pharma patent injunction; petition to terminate Google EPR; UPC, U.S. litigation news

1) Premium: Accord slapped with injunction in Munich after invalidity losses in EPO, German Federal Patent Court 

The Munich I Regional Court has found that Accord infringed TOWA’s dabigatran etexilate patent, issuing an injunction against the company. Dabigatran etexilate is an oral anticoagulant medicine that stops blood clots from forming, preventing strokes, deep vein thrombosis, and pulmonary embolism, among other things.

2) Free: Patent owner asks USPTO Director to terminate Google-triggered reexam, points to pattern of 21 do-overs after failed IPRs

K.Mizra has asked the USPTO Director to end a Google-triggered reexam, citing a pattern in which Google filed at least 21 ex parte reexams after losing IPR challenges.

3) Premium: UPC’s CD Munich: co-inventorship is not enough to revoke a patent for lack of entitlement

The CD Munich held that Art. 138(1)(e) EPC requires proof that the proprietor has no rights at all, so demonstrating co-inventorship cannot support revocation. The wind turbine patent is maintained as amended, less two dependent claims held insufficiently disclosed.

4) Premium: MediaTek targeted in PAE suit over DRAM and NAND patents originally assigned to SK hynix

Several of the asserted patents are relevant to the JEDEC DDR3 SDRAM standard.

5) Premium: Broadcom escalates patent infringement suits against Hyundai, Deutsche Telekom in UPC

Broadcom’s Avago and VMware have sued Hyundai and Deutsche Telekom, respectively, in the UPC’s Hamburg Local Division (LD), after already initiating disputes against each of the companies in the UPC’s Munich LD earlier this year.